Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Files An 8-K Entry into a Material Definitive Agreement
Item 1.01. Entry into a Material Definitive Agreement.

On February 6, 2017, Atara Biotherapeutics, Inc. (the “Company”) entered into a Standard Industrial Lease (the “Lease”) with Thousand Oaks Industrial Portfolio, LLC, a Delaware limited liability company (“Thousand Oaks”). The Lease provides for 90,580 of rentable square feet located in Thousand Oaks, California (the “Premises”). The term of the Lease is fifteen years (the “Initial Term”), which is currently expected to commence in the fourth quarter of 2017.

The base rent for the Premises to the Lease is $74,422.00 per month for the first year of the Initial Term, $76,654.66 per month for the second year of the Initial Term, $78,954.30 per month for the third year of the Initial Term, $81,322.93 per month for the fourth year of the Initial Term, $83,762.62 per month for the fifth year of the Initial Term, $86,275.50 per month for the sixth year of the Initial Term, $88,863.76 per month for the seventh year of the Initial Term, $91,529.67 per month for the eighth year of the Initial Term, $94,275.56 per month for the ninth year of the Initial Term, $97,103.83 per month for the tenth year of the Initial Term, $100,016.94 per month for the eleventh year of the Initial Term, $103,017.45 per month for the twelfth year of the Initial Term, $106,107.98 per month for the thirteenth year of the Initial Term, $109,291.22 per month for the fourteenth year of the Initial Term and $112,569.95 per month for the fifteenth year of the Initial Term. The Company will also pay Thousand Oaks maintenance expenses, property management fees and taxes related to the leased facility, and will be required to maintain certain insurance policies throughout the Initial Term.

The Company has the option to extend the Lease beyond the Initial Term for up to two renewal terms, the first such option to extend being for a period of ten years and the second such option to extend being for a period of nine years. The rental rate would be subject to market adjustment at the beginning of each renewal term.

The foregoing description of the Lease is only a summary and is qualified in its entirety by reference to the Lease, which will be filed as an exhibit to the Company’s Quarterly Report on Form 10-Q for the quarter ending March 31, 2017.

About Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. Its segment is the business of developing and commercializing therapeutics. It has approximately two groups of product candidates, such as allogeneic or third-party derived antigen-specific T-cells, and molecularly targeted biologics. Its T-cell product candidates include Epstein Barr Virus-cytotoxic T lymphocytes (EBV-CTL), which is in Phase II clinical trials for malignancies associated with EBV; cytomegalovirus (CMV)-CTL, which is in Phase II clinical trials for CMV, and Wilms Tumor 1 (WT1)-CTL, which targets cancers expressing the antigen WT1. Its molecularly targeted product candidates include STM 434, which is in Phase I clinical trial of STM 434 for ovarian cancer and other solid tumors; ATA 777, a fully human antibody targeting Activin A; ATA M43, a fully human anti-Actin-related protein 2-A (ActR2A)/2B monoclonal antibody; STM 217; ActR2B5, and ATA 842, a humanized antibody targeting myostatin.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Recent Trading Information

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) closed its last trading session up +0.05 at 15.10 with 375,702 shares trading hands.